Nature Communications (Jan 2024)
Identification of a highly conserved neutralizing epitope within the RBD region of diverse SARS-CoV-2 variants
- Yanqun Wang,
- An Yan,
- Deyong Song,
- Maoqin Duan,
- Chuangchuang Dong,
- Jiantao Chen,
- Zihe Jiang,
- Yuanzhu Gao,
- Muding Rao,
- Jianxia Feng,
- Zhaoyong Zhang,
- Ruxi Qi,
- Xiaomin Ma,
- Hong Liu,
- Beibei Yu,
- Qiaoping Wang,
- Mengqi Zong,
- Jie Jiao,
- Pingping Xing,
- Rongrong Pan,
- Dan Li,
- Juxue Xiao,
- Junbo Sun,
- Ying Li,
- Linfeng Zhang,
- Zhenduo Shen,
- Baiping Sun,
- Yanyan Zhao,
- Lu Zhang,
- Jun Dai,
- Jingxian Zhao,
- Lan Wang,
- Changlin Dou,
- Zheng Liu,
- Jincun Zhao
Affiliations
- Yanqun Wang
- State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University
- An Yan
- Cryo-electron Microscopy Center, Southern University of Science and Technology
- Deyong Song
- Antibody Research and Development Center, Shandong Boan Biotechnology Co., Ltd.
- Maoqin Duan
- Division of Monoclonal Antibodies, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC)
- Chuangchuang Dong
- Antibody Research and Development Center, Shandong Boan Biotechnology Co., Ltd.
- Jiantao Chen
- State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University
- Zihe Jiang
- Cryo-electron Microscopy Center, Southern University of Science and Technology
- Yuanzhu Gao
- Cryo-electron Microscopy Center, Southern University of Science and Technology
- Muding Rao
- Antibody Research and Development Center, Shandong Boan Biotechnology Co., Ltd.
- Jianxia Feng
- Antibody Research and Development Center, Shandong Boan Biotechnology Co., Ltd.
- Zhaoyong Zhang
- State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University
- Ruxi Qi
- Cryo-electron Microscopy Center, Southern University of Science and Technology
- Xiaomin Ma
- Cryo-electron Microscopy Center, Southern University of Science and Technology
- Hong Liu
- Antibody Research and Development Center, Shandong Boan Biotechnology Co., Ltd.
- Beibei Yu
- Antibody Research and Development Center, Shandong Boan Biotechnology Co., Ltd.
- Qiaoping Wang
- Antibody Research and Development Center, Shandong Boan Biotechnology Co., Ltd.
- Mengqi Zong
- Antibody Research and Development Center, Shandong Boan Biotechnology Co., Ltd.
- Jie Jiao
- Antibody Research and Development Center, Shandong Boan Biotechnology Co., Ltd.
- Pingping Xing
- Antibody Research and Development Center, Shandong Boan Biotechnology Co., Ltd.
- Rongrong Pan
- Antibody Research and Development Center, Shandong Boan Biotechnology Co., Ltd.
- Dan Li
- Antibody Research and Development Center, Shandong Boan Biotechnology Co., Ltd.
- Juxue Xiao
- State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University
- Junbo Sun
- Antibody Research and Development Center, Shandong Boan Biotechnology Co., Ltd.
- Ying Li
- Antibody Research and Development Center, Shandong Boan Biotechnology Co., Ltd.
- Linfeng Zhang
- Antibody Research and Development Center, Shandong Boan Biotechnology Co., Ltd.
- Zhenduo Shen
- Antibody Research and Development Center, Shandong Boan Biotechnology Co., Ltd.
- Baiping Sun
- Antibody Research and Development Center, Shandong Boan Biotechnology Co., Ltd.
- Yanyan Zhao
- Antibody Research and Development Center, Shandong Boan Biotechnology Co., Ltd.
- Lu Zhang
- Health and Quarantine Laboratory, Guangzhou Customs District Technology Centre
- Jun Dai
- Health and Quarantine Laboratory, Guangzhou Customs District Technology Centre
- Jingxian Zhao
- State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University
- Lan Wang
- Division of Monoclonal Antibodies, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC)
- Changlin Dou
- Antibody Research and Development Center, Shandong Boan Biotechnology Co., Ltd.
- Zheng Liu
- Cryo-electron Microscopy Center, Southern University of Science and Technology
- Jincun Zhao
- State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University
- DOI
- https://doi.org/10.1038/s41467-024-45050-3
- Journal volume & issue
-
Vol. 15,
no. 1
pp. 1 – 15
Abstract
Abstract The constant emergence of SARS-CoV-2 variants continues to impair the efficacy of existing neutralizing antibodies, especially XBB.1.5 and EG.5, which showed exceptional immune evasion properties. Here, we identify a highly conserved neutralizing epitope targeted by a broad-spectrum neutralizing antibody BA7535, which demonstrates high neutralization potency against not only previous variants, such as Alpha, Beta, Gamma, Delta and Omicron BA.1-BA.5, but also more recently emerged Omicron subvariants, including BF.7, CH.1.1, XBB.1, XBB.1.5, XBB.1.9.1, EG.5. Structural analysis of the Omicron Spike trimer with BA7535-Fab using cryo-EM indicates that BA7535 recognizes a highly conserved cryptic receptor-binding domain (RBD) epitope, avoiding most of the mutational hot spots in RBD. Furthermore, structural simulation based on the interaction of BA7535-Fab/RBD complexes dissects the broadly neutralizing effect of BA7535 against latest variants. Therapeutic and prophylactic treatment with BA7535 alone or in combination with BA7208 protected female mice from the circulating Omicron BA.5 and XBB.1 variant infection, suggesting the highly conserved neutralizing epitope serves as a potential target for developing highly potent therapeutic antibodies and vaccines.